This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Weijun Chen, PhD
Director, RNA Technologies Lead at Intellia Therapeutics


Weijun Chen is an expert in RNA technologies with over 20 years of industrial and academic experience. His areas of focus include RNA-based therapeutics platform development from research concepts to clinical development. Since joining Intellia in January 2019, Weijun has served across several roles with a focus in RNA technologies, such as RNA innovation and design, RNA manufacturing, and RNA analytical development. Currently as the Director of RNA Technologies at Intellia, Weijun is responsible for providing RNA products to support platform needs and has technical oversight to improve RNA for Cas9 and new editing modalities. Prior to Intellia, Weijun was an assistant professor at University of Massachusetts Medical School in the RNA Therapeutic Institute for more than 10 years. He holds a Ph.D. in Chemistry from the University of Science and Technology of China.

Agenda Sessions

  • mRNA Design, Synthesis, and Characterization for Gene Editing